A direct switch from MDI to the Omnipod 5 AID (automated insulin delivery; hybrid closed-loop) System produced clinically significant glucose improvements within 13 weeks, signalling a practical leap forward in improved diab
In automated insulin delivery (AID) (also known as hybrid closed-loop) systems, reliable connectivity between continuous glucose monitor (CGM) sensors and the insulin delivery device is essential.
The Omnipod 5 Automated Insulin Delivery (AID) System is a transformative step in diabetes care. The system merges the benefits and simplicity of a wearable, tubeless design with AID technology.
For individuals living with diabetes, wearable technologies like such as continuous glucose monitors (CGMs) and insulin pumps are transformative tools that simplify disease management. However, for 25–40% of users, skin reactions present a common yet underappreciated challenge.
When making treatment decisions for type 1 diabetes (T1D), healthcare professionals increasingly rely on real-world data to understand how therapies perform outside of clinical trials. A recent study— Aleppo G et al. Diabetes Ther. 2023.
Helping people with type 1 diabetes (T1D) stay active has long been a balancing act. Exercise can improve metabolic health and quality of life but also increases the risk of glycaemic variability and hypoglycaemia.1,2